Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication (Q34570815)

3 August 2017

Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication (English)

1 reference

Helicobacter pylori infectious disease

3 August 2017

0 references

1 reference

9

Giovanni Gasbarrini

1 reference

3 August 2017

7

Cristiano Spada

1 reference

3 August 2017

Enrico C Nista

1

1 reference

3 August 2017

Marcello Candelli

2

1 reference

3 August 2017

Maria A Zocco

3

1 reference

3 August 2017

Filippo Cremonini

4

1 reference

3 August 2017

Veronica Ojetti

5

1 reference

3 August 2017

Rosalba Finizio

6

1 reference

3 August 2017

Giovanni Cammarota

8

1 reference

3 August 2017

Antonio Gasbarrini

10

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

The American Journal of Gastroenterology

3 August 2017

1 reference

3 August 2017

101

1 reference

3 August 2017

9

1 reference

3 August 2017

1985-1990

1 reference

Antibacterial treatment of gastric ulcers associated with Helicobacter pylori

3 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Treatment of H. pylori infection: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Levofloxacin based regimens for the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Bactericidal properties of moxifloxacin and post-antibiotic effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Effect of quinolones on intestinal ecology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00716.X

10.1111/J.1572-0241.2006.00716.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference